@article{42266d7c1c8a463fa4dc7b476af7cbfc,
title = "Reply",
author = "Campochiaro, {Peter A.} and Maass, {Katie F.} and Natasha Singh and Giulio Barteselli",
note = "Funding Information: Financial Disclosures: The authors made the following disclosures: P.A.C.: Advisory board ‒ Aerpio, Allegro, Applied Genetic Technologies Corporation, Exonate, Genentech, Inc., Merck; Cofounder ‒ Graybug Vision; Consultant ‒ Alimera, Allergan, AsclepiX, Astellas, Graybug Vision, Intrexon, Novartis, RXI; Equity owner ‒ Allegro, Graybug Vision; Honoraria ‒ Applied Genetic Technologies Corporation, AsclepiX, Astellas, Exonate, Genentech, Inc., Graybug Vision, Intrexon, Merck, Novartis, RXI; Financial support ‒ Aerpio, Alimera, Allegro, Allergan, AsclepiX, Clearside, Genentech, Inc., Graybug Vision, Oxford Biomedica, Regeneron, Regenxbio, RXI, Sanofi Genzyme.",
year = "2019",
month = nov,
doi = "10.1016/j.ophtha.2019.06.020",
language = "English (US)",
volume = "126",
pages = "e88--e89",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "11",
}